Mastitis in cows

Selected Species


Symptoms, causes, treatment and prevention

Mastitis is one of the most prevalent and costly diseases of dairy cows worldwide. The estimated annual cost to the US dairy industry alone is US$2 billion. The causes and management of bovine mastitis are complex, but various measures can be implemented to optimize udder health and productivity in dairy herds.

Definition and causes

Mastitis is an inflammation of the mammary gland generally associated with intramammary infection (IMI). Bacteria are the most common etiological agent, but other microbes such as fungal species (yeasts or molds), certain microscopic algae (Prototheca spp.), and viruses can cause IMI. Physical trauma or chemical irritation are less common causes of mastitis.


A link between mastitis and endotoxins in high producing dairy cows? Remarks from James Cullor of the School of Veterinary Medicine, University of California – Davis (USA) at the 2016 World Nutrition Forum

Costs to dairy producers

Economic losses stem from reduced milk production and decreased milk quality. Farmers must discard milk from cows with clinical cases of mastitis and from cows undergoing antibiotic treatment according to withdrawal periods in order to provide time for antibiotics to clear the cow’s body. 

Mastitis also alters the composition and properties of milk, resulting in reduced cheese yields and reduction of shelf life of manufactured dairy products. Treatment costs and veterinary costs rise, as do labor costs, and milking parlor efficiency can decrease due to increased time spent attending to mastitic animals.

In addition to economic losses, animal welfare is a concern as studies have shown that mastitis can be painful and cause discomfort to cows. Thus, cows diagnosed with clinical mastitis, or those with persistent subclinical mastitis have a greater risk of being culled. 

Indeed, udder health issues are frequently cited as one of the top three reasons for culling of dairy cows. Low milk production, potentially associated with mastitis, is another leading cause of culling in dairy herds. Toxic mastitis, an acute form of the disease resulting in severe inflammation and septicemia, can even lead to cow death.

Mastitis categories

There are multiple ways to classify cases of mastitis.

The first major classification has to do with the origin of the pathogen: contagious vs. environmental (Table 1). A broad spectrum of bacteria have been isolated from infected mammary gland secretions, but a relatively small array of species are frequently detected. 

Contagious pathogens are spread cow-to-cow, typically during milking as infected mammary glands serve as the primary reservoir for such microbes. Contagious pathogens include Staphylococcus aureusStreptococcus agalactiae, and Mycoplasma spp.

Environmental pathogens are those which primarily reside in the cow’s normal habitat. Cows are primarily exposed to these pathogens between milkings when teat ends come in contact with contaminated bedding, manure, contaminated water, or soil. Common environmental pathogens include Escherichia coliKlebsiella spp., and environmental streptococci such as S. uberis and S. dysgalactiae. There are many other microorganisms that have been isolated from cases of mastitis and are associated with the cow’s environment.

Coagulase negative staphylococci (CNS) are normal flora of the skin and these organisms can act as opportunistic pathogens when they enter the mammary gland. A hot topic in the world of mastitis research revolves around differentiating CNS to better understand the differences in their effects on milk quality and yield. 

 Contagious mastitisEnvironmental mastitis
ReservoirInfected mammary glandsThe cow’s environment, including: 
  •    - Bedding/stalls/soil
  •    - Manure
  •    - Water
Exposure Spread from cow-to-cow, including via:
  • - Milking equipment
  • - Milkers’ hands or towels
  • - Flies and other vectors
Constant exposure exacerbated by heat and humidity

Table 1. Contagious and environmental mastitis | Source: BIOMIN

The distinction of acute vs. chronic mastitis has to do with the timing and duration of the disease (Table 2). 

Acute mastitisChronic mastitis
Sudden onset, but often quickly resolvedContinues over a long period of time
Redness, swelling, hardnessOften subclinical
PainPotentially painful
Grossly abnormal milk‘Flare-ups’ or periodic acute events
Noticeable decrease in milk yieldLess obvious decrease in milk yield

Table 2. Signs of acute and chronic mastitis | Source: BIOMIN

Differentiation of clinical vs. subclinical mastitis is determined by the presentation of the disease. Clinical cases are relatively easy to identify due to the presence of visual changes or abnormalities of the milk and/or mammary gland. 

Clinical cases may present with any of the following signs: 

  • Flakes or clots to purulent exudate 
  • Discolored, watery, or bloody milk 
  • Swelling or hardening of the gland
  • The presence of pain, heat or reddish discoloration of the skin of inflamed glands

Systemic signs of illness may also occur, including: 

  • Increased rectal temperature 
  • Anorexia
  • Decreased reticulorumen motility
  • Lethargy 
  • Potentially death 

Severity of clinical mastitis cases can range from mild to severe. The clinical rating depends of the range and severity of the symptoms observed. 

In contrast, subclinical mastitis cases often go unrecognized, as the milk and gland appear normal. Although subclinical mastitis is more difficult to identify, monitoring of somatic cell count (SCC) or bacteriological culturing of milk can detect the presence of inflammation or IMI. 

The different mastitis classifications are not mutually exclusive. For instance, a cow could have an acute clinical case of environmental mastitis.

Predisposing factors

As a multifactorial disease, mastitis has many causes and predisposing factors which are outlined in Table 3.


Coordinating the delivery of fresh feed while cows are in the parlor will entice cows to eat and remain standing upon return to the pen. This provides time for the teats end to close and limits exposure to pathogens following milking.

Milking parlor management

Milking parlor management including milking routine best practices is essential to limiting mastitis risk in a herd. The milking system must be well maintained to ensure properly functioning, clean equipment is used to harvest milk. Relatively few intramammary infections are attributed to correctly functioning milking machines.

However, improperly functioning milking equipment can result in a high rate of new intramammary infection. Proper milk line vacuum and the duration of milking must be optimized as over-milking can damage the teat end, increasing the likelihood of mastitis. Insufficient milk removal can also predispose cows to mastitis and decrease overall milk production. 

Defense mechanisms

There are anatomical, cellular, and soluble defense mechanisms that help protect the mammary gland from infection. Pathogens must gain entry into the mammary gland via the teat canal in order to cause IMI. The first line of defense against IMI is the innate immune system. Anatomical features of the teat serve as physical barriers that help prevent establishment of infection.

The teat sphincter muscles keep the teat opening closed between milkings. Post-milking, the teat sphincter muscles can take at least 2 h to close the teat opening, so this period is crucial for mammary defense. Additionally, the teat canal is lined with a waxy substance called keratin that has antimicrobial properties to help impede pathogen infiltration into the gland.


Since the environment plays a large role in mammary health, good hygiene in the parlor as well as in the barn are essential to reducing mastitis risk. Clean sand bedding is considered the gold standard, as inorganic material does not support the growth of pathogens. The greater the organic content of the sand, the less protective it will be. 


Factors beyond control, including the weather, also increase the risk of mastitis. Increased temperatures and humidity better support pathogen growth in the cow’s environment as well as increase stress in the cow, reducing her resistance to infection.


Nutrition can also play a role in mastitis risk. Cows in negative energy balance, especially transition cows, are more susceptible to infection. Diets must also meet vitamin and mineral requirements for proper immune function. 

Flooring and flow

Surfaces and alleys moving into the parlor as well as the holding pen must provide firm footing and cow flow should be smooth (a combination of good design and stress free handling) thus reducing the risk of physical injury to teats. Damage to teat end tissue facilitates bacterial entry into the gland.

Table 3. Predisposing factors of mastitis | Source: BIOMIN

Improperly working milking equipmentEnvironment ManagementImmune suppression
- Teat end damage
- Over-milking
- Genetics 
  •      - Resistance
  •      - Mammary structure
  •      - Age
  •  - Milking routine including pre- and post-dip application
  •  - Hygiene – milking parlor and barn
  •  - Bedding
  •  - Nutrition
  •  - Vaccination program
  •  - Dry cow therapy
  •  - Transition cow management
  •  - Heifer management
  •  - Transition period
  •  - Mycotoxins

Mycotoxins can influence the immune system of animals. Cows experience a great deal of stress around parturition due to the many physiological changes which occur with calving and the onset of lactation. Mycotoxins in cattle feed can exacerbate this stress via immune suppression and decreased feed intake, deepening negative energy balance and increasing the risk of metabolic disorders and infectious diseases.

Deoxynivalenol (DON) and other trichothecenes can disrupt protein synthesis which can reduce white blood cell populations and condition and limit production of important inflammatory mediators. In addition, some of the ergots and trichothecenes can cause dermal lesions and gangrenous necrosis that disrupt the integrity of the teat and the teat skin, contributing to an increased risk of mastitis.

Table 4 highlights some of the main consequences of mycotoxins in dairy cows in relation to mammary health and milk production. Reduced milk production results from several factors, including a decrease in intake or feed refusal that is commonly reported with certain mycotoxins such as DON. Mycotoxins can alter rumen function by changing the microbial populations or the breakdown of nutrients, consequently reducing nutrient absorption and impairing metabolism which ultimately leads to reduced availability of the precursors needed for milk synthesis.

1. Reduced milk production
2. Toxic contaminants in milk, especially Aflatoxin M1
3. Increased risk of mastitis
4. Altered milk composition

Table 4. Potential mammary-related negative effects of mycotoxins in dairy cows | Source: BIOMIN

Reduced milk quality

Reduced milk quality stems primarily from increased SCC. Somatic cells, specifically neutrophils, increase in number in the mammary gland during mastitis to combat invading pathogens. Mycotoxins can reduce neutrophil function, making the cow’s immune response less effective, which in turn increases the severity and duration of infection. 

Additionally, mastitis causes alterations in the concentration of milk components including changes in fat, protein, lactose, and mineral content. Compared with milk from healthy cows, that of affected cows can show mineral changes that include increased sodium and reduced potassium levels.

These differences negatively impact the manufacturing quality of milk. Milk processors want to obtain the highest quality milk to improve the yield and shelf life of manufactured products such as cheese. 

5 strategies to prevent bovine mastitis

1. Hygiene

Since the milking equipment can serve as a fomite (inanimate object which can transfer infection), proper hygiene is essential.

2. Disinfection and dry cow therapy

The use of post-milking disinfectant teat dip and antibiotic dry cow therapy has helped to reduce the prevalence of contagious mastitis. Environmental pathogens are less likely to be spread during milking. Usage of germicidal pre-milking teat dip prior to milking can further reduce this risk.

The dry period is critical for good udder health and optimal productivity in the following lactation. Use of antimicrobial dry cow therapy (DCT) provides an opportunity to eliminate existing IMI and provides protection against new IMI during the early dry period. This period of non-lactation gives producers an opportunity to treat existing IMI without losses associated with discarded milk due to antimicrobial treatment. However, the periods immediately following dry-off and before calving are associated with an increased susceptibility to new IMI.

A schematic illustration of the incidence of new intramammary infection during the lactation cycle. The peak in new infection rate, after drying off, is considerably higher in cows not receiving any form of dry cow therapy.
Source: Bradley and Green, 2004

3. Management

Various management practices have helped with prevention of mastitis in cows caused by contagious pathogens, but have not proven to limit environmental infections. Well-managed herds have been successful in limiting contagious IMI. However, environmental mastitis has continued to be a challenge since even the cleanest stalls and surroundings can harbor microorganisms. Control of contagious IMI is possible and repeatable across herds when implementing these practices. The fight against mastitis has refocused on limiting the prevalence of environmental IMI.

4. Vaccines

Vaccines have been designed to combat mastitis, but many are of limited protection against coliform infections. Studies have shown that the J5 core antigen vaccine is efficacious in reducing the incidence of clinical mastitis caused by E. coli, especially during early lactation, but did not reduce the prevalence of infection. Vaccines can be valuable in reducing the duration and severity of IMI. The benefits of use of the J5 vaccine have been proven worthwhile since the mid-1990s.

5. Mycotoxin risk management

Feed should be monitored for the presence of mycotoxins and an effective mycotoxin counteracting product or toxin binder should be incorporated into the feed. Mycofix® contains an EU authorized aflatoxin binder, the only product to have been successfully evaluated through the EU registration process for aflatoxin deactivation. 

For the less adsorbable mycotoxins such as DON that pose an increased risk of mastitis and other challenges, biotransformation rather than binding is the effective approach. Mycofix® has proven biotransformation activity on DON and other trichothecenes, zealarenone (ZEN), ochratoxin A and fumonisins.  In addition, Mycofix® bioprotection components support the liver and immune system. The figure shows how dairy cows (exposed to DON and ZEN in their feed) had a reduced incidence of mastitis when receiving Mycofix® Plus. Considerable data shows that Mycofix® can increase milk production, decrease somatic cell count, reduce toxic contaminants in milk, and help maintain or improve milk component content in the face of mycotoxin contamination.

Mycofix® Plus and the incidence of mastitis | Source: BIOMIN trial in Slovakia, 2011


Bannerman, D.D., A.C.W. Kauf, M.J. Paape, H.R. Springer, and J.P. Goff. 2008. Comparison of Holstein and Jersey innate immune responses to Escherichia coli intramammary infection. J. Dairy Sci. 91:2225-2235.

Burvenich, C., V. van Merris, J. Mehrzad, A. Diez-Fraile, and L. Duchateau. 2003. Severity of E. coli mastitis is mainly determined by cow factors. Vet. Res. 34:521-564.

Bradley, A.J., and M.J. Green. 2004. The importance of the nonlactating period in the epidemiology of intramammary infection and strategies for prevention. Vet. Clin. Food Anim. 20: 547-568.

Harmon, R.J. 1994. Physiology of mastitis and factors affecting somatic cell counts. J. Dairy Sci. 77:2103-2112.

Hogan, J.S. and K.L. Smith. 2003. Coliform mastitis. Vet. Res. 34:507-519.

Hogan, J.S., K.L. Smith, K.H. Hoblet, P.S. Schoenberger, D.A. Todhunter, W.D. Hueston, D.E. Pritchard, G.L. Bowman, L.E. Heider, B.L. Brockett, and H.R. Conrad. 1989. Field survey of mastitis in low somatic cell count herds. J. Dairy Sci. 72:1547-1556.

Hogan, J.S., K.L. Smith, D.A. Todhunter, and P.S. Schoenberger. 1992a. Field trial to determine the efficacy of an Escherichia coli J5 mastitis vaccine. J. Dairy Sci. 75:78-84.

Hogan, J.S., W.P. Weiss, D.A. Todhunter, K.L. Smith, and P.S. Schoenberger. 1992b. Efficacy of an Escherichia coli J5 mastitis vaccine in an experimental challenge. J. Dairy Sci. 75:415-422.

Hogan, J.S., W.P. Weiss, K.L. Smith, D.A. Todhunter, P.S. Schoenberger, and L.M. Sordillo. 1995. Effects of an Escherichia coli J5 vaccine on mild clinical coliform mastitis. J. Dairy Sci. 78:285-290.

Leslie, K. E. and C. S. Petersson-Wolfe. 2012. Assessment and management of pain in dairy cows with clinical mastitis. Vet. Clin. North Am. Food Anim. Pract. 28:289-305. http://dx/

National Mastitis Council. 2016. Current Concepts of Bovine Mastitis, 5th ed. The National Mastitis Council, Inc.

National Mastitis Council. 1999. Laboratory Handbook on Bovine Mastitis-Revised Edition. The National Mastitis Council, Inc.

NMC. 2004. Microbial Procedures for the Diagnosis of Bovine Udder Infection and Determination of Milk Quality. The National Mastitis Council, Inc.

Smith, K.L., D.A. Todhunter, and P.S. Schoenberger. 1985. Environmental mastitis: cause, prevalence, prevention. J. Dairy Sci. 68:1531-1553.

Sordillo, L.M. and K.L. Streicher. 2002. Mammary gland immunity and mastitis susceptibility. J. Mammary Gland Bio. And Neoplasia. 7:135-146.

Wellenberg, G.J., W.H.M. van der Poel, and J.T. van Oirschot. 2002. Viral infections and bovine mastitis: a review. Veterinary Microbiology. 88:27-45.

Zhao, X., and P. Lacasse. 2008. Mammary tissue damage during bovine mastitis: causes and control. J. Anim. Sci. 86(Suppl. 1):57-65.

Mastitis Solutions

  • Mycofix®

    The Mycofix® portfolio of feed additives represents the most state-of-the-art solution for protecting animal health by deactivating mycotoxins that contaminate farm animal feed. Its safety and efficacy are proven by 7 EU authorizations for substances that deactivate mycotoxins.

  • ROVIMIX® E50

    ROVIMIX® E50 is a superior formulation of vitamin E, which strengthens the immune system and increases performance in poultry, swine and dairy cows.